Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUC-1031 plus cisplatin in untreated advanced biliary tract cancer
NCT04163900Phase 3Terminated
- Sponsor
- NuCana
- Start
- Dec 2019
- Primary completion
- Mar 2022
- Modality
- Metabolically Activated Prodrugs
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of gemcitabine monophosphate ProTide in biliary tract cancer (BTC) (2 arms), sponsored by NuCana. Primary endpoints: Objective Response Rate at 6 months and Overall Survival at 12 months. Started Dec 2019; status: terminated.
02
Drugs
gemcitabine monophosphate ProTide
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04163900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163900.